FRONTEO, Inc.

Business Details

Leveraging its proprietary natural language processing AI technology "KIBIT," the company operates in two fields: AI Drug Discovery (Drug Discovery AI Factory) and AI Medical Devices (SDS-881, etc.). It has built four business models: co-creation projects with pharmaceutical companies, a comprehensive co-creation model, the DDAIF Innovation Bridge, and in-house research. In FY2026 (ending March 2026), revenue expanded sharply, up 191.4% year on year, driven by the accumulation of co-creation projects and early revenue contribution from DDAIF Innovation Bridge deals.

Recent Overview

The AI Drug Discovery field expanded sharply, up 511.7% year on year, and the segment operating loss narrowed significantly

Life Science AI Business revenue for FY2026 (ending March 2026) was ¥1,033 million (up 191.4% year on year). The AI Drug Discovery field posted ¥752 million (up 511.7% year on year), driven by the accumulation of co-creation projects (new projects launched with more than 10 companies including EA Pharma, Chugai Pharmaceutical, Santen Pharmaceutical, and Nippon Kayaku) and early revenue contribution from DDAIF Innovation Bridge deals. The AI Medical Device field posted ¥281 million (up 21.5% year on year), driven by monetization of Talk Lab KIBIT. The operating loss narrowed to ¥16 million (from a loss of ¥232 million in the prior period). The business ecosystem also expanded, including the conclusion of a basic agreement on joint research with UBE and the start of joint research with the University of Oklahoma in the United States.

Key Products

Growth Drivers

• Continued accumulation of co-creation projects in the AI drug discovery field (launch of new projects with multiple major pharmaceutical companies)
• Generation of joint pipeline derivation and licensing revenue through collaboration with bio-ventures via the DDAIF Innovation Bridge
• Deepening of the comprehensive co-creation model (conclusion of a strategic business alliance with Maruishi Pharmaceutical) creating non-continuous, success-fee-based revenue opportunities
• Progress toward approval and commercialization of the AI medical device (SDS-881) within FY2026 (ending March 2026), co-developed with Shionogi & Co.
• Expansion of Talk Lab KIBIT alliances with insurance companies and financial institutions (horizontal expansion building on implementation track record with Nippon Life and Asahi Life)
• Expansion of the AI drug discovery business into the U.S. market (strategic partnership agreement with Q Partners LLC, joint research with the University of Oklahoma)
• Establishment of an integrated research framework from hypothesis generation to experimental verification through placement of a joint research base at the Institute of Science Tokyo
• Expanding demand from domestic pharmaceutical companies driven by the Japanese government's policy package to strengthen drug discovery capabilities (announced December 2024)

Risks

• The Life Science AI Business continued to post an operating loss of ¥16 million in FY2026 (ending March 2026), and there is uncertainty as to the timing of profitability given accelerating future investment in human capital
• Obtaining regulatory approval and commercializing the AI medical device (SDS-881) is subject to timeline risk dependent on the PMDA's review process
• The generation of deliverables from co-creation projects and their transition to the next phase depend on the R&D decisions of partner pharmaceutical companies, creating uncertainty in the timing of revenue recognition
• Funding support, including investments in bio-ventures through the DDAIF Innovation Bridge, carries investment recovery risk
• Expansion of the AI drug discovery business into the U.S. market is at an early stage, and there is uncertainty regarding the time and cost required for commercialization and monetization
• Although profitability of the Life Science AI Business is planned for FY2027 (ending March 2027), achievement depends on the timing of revenue contribution from co-creation projects